Advertisement

Topics

AngioDynamics Announces First Patient Enrolled in NanoKnife® DIRECT Clinical Study

11:59 EDT 13 May 2019 | Investing News Network

AngioDynamics (NASDAQ:ANGO) has announced it has enrolled the first patient in its NanoKnife Irreversible Electroporation (IRE) “Data IRE Cancer Treatment” clinical study (DIRECT). As quoted in the press release: The DIRECT Study supports a proposed expanded indication for the NanoKnife System in the treatment of Stage III pancreatic cancer. The first patient enrollment closely follows … Continued

The post AngioDynamics Announces First Patient Enrolled in NanoKnife® DIRECT Clinical Study appeared first on Investing News Network.

Original Article: AngioDynamics Announces First Patient Enrolled in NanoKnife® DIRECT Clinical Study

NEXT ARTICLE

More From BioPortfolio on "AngioDynamics Announces First Patient Enrolled in NanoKnife® DIRECT Clinical Study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Pancreatic Cancer
The pancreas secretes a number of important hormones into the digestive tract and the blood stream. Cancers are most commonly exocrine than endocrine (neuroendocrine) tumors. Functional tumors secrete hormones; Insulinoma, Gastrinoma, Somatostatinoma, VI...